The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study

Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shi...

Full description

Bibliographic Details
Main Authors: Yesol Jung, Bohee Won, Mijung Lee, Jinyoung Chung, Sung Ju Han, Manho Kim
Format: Article
Language:English
Published: Hindawi Limited 2019-01-01
Series:Evidence-Based Complementary and Alternative Medicine
Online Access:http://dx.doi.org/10.1155/2019/2363420
id doaj-658317799bda4365b068b23e9a448f49
record_format Article
spelling doaj-658317799bda4365b068b23e9a448f492020-11-25T01:37:50ZengHindawi LimitedEvidence-Based Complementary and Alternative Medicine1741-427X1741-42882019-01-01201910.1155/2019/23634202363420The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot StudyYesol Jung0Bohee Won1Mijung Lee2Jinyoung Chung3Sung Ju Han4Manho Kim5Department of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Veterinary Medicine, Kangwon National University, Chuncheon, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaDepartment of Neurology, Seoul National University Hospital, Seoul, Republic of KoreaObjective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue medications frequency were measured from each patient’s headache diary. The modified Migraine Disability Assessment (MIDAS) questionnaires to assess migraine associated disabilities were also completed at each visit. The serum calcitonin gene-related peptide (CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. Results. The monthly migraine frequency was significantly reduced from 20.5 days at baseline to 16.4 days at week 12 (P =0.003), and 22% of the participants showed ≥ 50% reduction. The frequency reduction was observed by week 4 (P =0.035) and continuously occurred through week 8 (P =0.001) and week 12 (P =0.003). The rescue medications frequency also decreased significantly from 17.4 days at baseline to 13.2 days at week 12 (P =0.035). Lastly, the serum CGRP concentration dropped from 434.6 pg/mL at baseline to 371.4 pg/mL at week 12, which was statistically significant (P <0.001). Conclusions. Shinbaro demonstrated prophylactic effects in migraine patients, significantly reducing their mean migraine frequency, rescue medications frequency, and the serum CGRP concentration after 12 weeks of treatment. This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758).http://dx.doi.org/10.1155/2019/2363420
collection DOAJ
language English
format Article
sources DOAJ
author Yesol Jung
Bohee Won
Mijung Lee
Jinyoung Chung
Sung Ju Han
Manho Kim
spellingShingle Yesol Jung
Bohee Won
Mijung Lee
Jinyoung Chung
Sung Ju Han
Manho Kim
The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
Evidence-Based Complementary and Alternative Medicine
author_facet Yesol Jung
Bohee Won
Mijung Lee
Jinyoung Chung
Sung Ju Han
Manho Kim
author_sort Yesol Jung
title The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
title_short The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
title_full The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
title_fullStr The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
title_full_unstemmed The Efficacy of Shinbaro for the Preventive Treatment of Migraine: A Pilot Study
title_sort efficacy of shinbaro for the preventive treatment of migraine: a pilot study
publisher Hindawi Limited
series Evidence-Based Complementary and Alternative Medicine
issn 1741-427X
1741-4288
publishDate 2019-01-01
description Objective. To investigate the therapeutic potential and efficacy of Shinbaro, an herbal medication for inflammatory diseases and bone disorders, as a preventive treatment of migraine. Methods. In this prospective, interventional, single-arm, pre-post study, 37 migraine patients took 600mg bid of Shinbaro for 12 weeks. At 4-week intervals, the migraine frequency and the rescue medications frequency were measured from each patient’s headache diary. The modified Migraine Disability Assessment (MIDAS) questionnaires to assess migraine associated disabilities were also completed at each visit. The serum calcitonin gene-related peptide (CGRP) concentrations before and after 12 weeks of Shinbaro administration were compared. Results. The monthly migraine frequency was significantly reduced from 20.5 days at baseline to 16.4 days at week 12 (P =0.003), and 22% of the participants showed ≥ 50% reduction. The frequency reduction was observed by week 4 (P =0.035) and continuously occurred through week 8 (P =0.001) and week 12 (P =0.003). The rescue medications frequency also decreased significantly from 17.4 days at baseline to 13.2 days at week 12 (P =0.035). Lastly, the serum CGRP concentration dropped from 434.6 pg/mL at baseline to 371.4 pg/mL at week 12, which was statistically significant (P <0.001). Conclusions. Shinbaro demonstrated prophylactic effects in migraine patients, significantly reducing their mean migraine frequency, rescue medications frequency, and the serum CGRP concentration after 12 weeks of treatment. This study is registered in Clinical Research Information Service, Seoul National University Hospital Clinical Research Institute (IRB No. 1604-138-758).
url http://dx.doi.org/10.1155/2019/2363420
work_keys_str_mv AT yesoljung theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT boheewon theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT mijunglee theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT jinyoungchung theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT sungjuhan theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT manhokim theefficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT yesoljung efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT boheewon efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT mijunglee efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT jinyoungchung efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT sungjuhan efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
AT manhokim efficacyofshinbaroforthepreventivetreatmentofmigraineapilotstudy
_version_ 1725057036243173376